Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Functional classification of monoallelic TP53 mutations refines prognostic stratification in myelodysplastic neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

EAEva AltrockWHWolf‐Karsten Hofmann

Discussion

Loading...

Member takes

Overview

Observational analysis found dominant-negative TP53 mutations worsen overall survival in myelodysplastic neoplasms, indicating refined stratification is crucial.

Key Points

  • Overall survival was significantly worse for MDS patients with monoallelic TP53 mutations classified as dominant-negative.
  • Patients with dominant-negative TP53 mutations and a high phenotypic score had a median survival of 13.8 months vs. 39.2 months for lower scores.
  • Functional characteristics of TP53 mutations were assessed using high-throughput saturation mutagenesis.
  • Integrating functional mutation data may enhance risk models for myelodysplastic neoplasms.

Cite This Study

Altrock et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d825https://doi.org/10.1182/blood-2025-3835
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of TP53 mutation status and variant allele frequency in myelodysplastic syndromes: A meta-analysis of prognosis and transplant outcomes2025
  2. 2Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type2025 · 4 citations
  3. 3Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  4. 4Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  5. 517p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease2025